



# Annual and Extraordinary Shareholders Meetings

## Biocartis Group NV

8 May 2020

### Questions and answers

The below translation in English is a free translation. Please see the Dutch version for the original questions & answers.

Question	Answer
<p>1. <i>"What is the current status of Biocartis in China and South-East Asia?"</i></p>	<p>In Q1 2020, the Biocartis joint venture with Guangzhou Wondfo Biotech Co., Ltd. ("China JV") further prepared for the commercialization of the Idylla™ platform in China with a primary focus on realizing local production capacity and product registrations.</p> <p>In Japan, distribution partner Nichirei Biosciences and Biocartis continued to work on the ongoing Idylla™ test IVD registration preparations for the Japanese market in Q1 2020.</p>
<p>2. <i>"Why is the pre-emptive right of the shareholders limited or canceled in the event of a capital increase (with the issue of new shares)? Doesn't this lead to favoritism, possibly self-interest and personal benefits?"</i></p>	<p>The proposed resolution of the general meeting concerns the renewal of the authorized capital. This concerns the authorization by the shareholders to the board of directors to increase the capital with the cancellation of the preferential subscription right. Such authorization requires a majority of 75% of the votes cast by the shareholders.</p> <p>Upon use of the authorized capital, the preferential subscription right is canceled only after decision of the board of directors and in the interest of the company. One of the main reasons for this is the speed with which capital can be raised in such a situation. This is necessary in order to be able to respond quickly to any market opportunities.</p> <p>When the preferential subscription right is lifted, this by no means involves favoritism for the benefit of certain parties. The bank syndicate which is always involved in a capital round is a neutral party and always makes an objective proposal to the Company in terms of which investors they propose to join the capital and for what amount. These criteria are objective and diverse, for example, whether or not an investor's long-term horizon, and these criteria are always set in advance.</p> <p>More information on the proposal to renew the authorized capital can be found in the <a href="#">special report of the board of directors</a>.</p>